乳腺癌拓扑异构酶Ⅱα基因HER-2基因及Ki-67的关系研究

TopoisomeraseⅡα gene HER-2 gene and Ki-67 in breast cancer: a correlation study

目的探讨乳腺癌拓扑异构酶Ⅱα基因(TOP2A)、人类表皮生长因子受体2(HER-2)基因及Ki-67的关系。方法采用免疫组织化学的方法检测142例乳腺癌患者Ki-67分级,采用显色原位杂交(CISH)检测人类HER-2,荧光原位杂交(FISH)法检测TOP2A的扩增或缺失情况。结果本组142例中,Ki-67(-)21例,+48例,++53例,+++20例。TOP2A基因扩增19例,未扩增123例。Ki-67分级与TOP2A基因扩增无关联(χ2=1.28,P>0.05)。HER-2基因扩增72例,TOP2A基因同步扩增16例。TOP2A基因和HER-2基因扩增结果之间有关联(χ2=8.30,P<0.01)。结论 TOP2A基因扩增主要存在于HER-2基因扩增患者中,与Ki-67及病理分级无关联。TOP2A基因用于乳腺癌预后分析的价值有待研究。

Objective To investigate the correlation between TopoisomeraseⅡα（TOA2A） gene and Ki-67 and between HER-2 and Ki-67 in breast cancer. Methods The Ki-67 grading of 142 patients with breast cancer was detected by immunohistochemistry （IHC）, human HER-2 by Chromogenic in situ hybridization （CISH） and the amplification or deficiency of TOP2A by fluorescence in situ hybridization （FISH）. Results Of 142 cases, there were 21 cases of Ki-67（-）, 48 cases of （＋）, 53 cases of （＋＋） and 20 cases of （＋＋＋）. The TOP2A gene was amplified in 19 cases and not amplified in the remaining 123 cases. The grading of Ki-67 had no association with the amplification of TOP2A （ χ2=1.28, P0.05）. There were 72 cases of HER-2 gene amplification and 16 cases of synchronous amplification of TOP2A gene. TOP2A gene was associated with the amplification of HER-2（ χ2=8.30,P0.01）. Conclusion The amplification of TOP2A gene was found to exist in patients with amplified HER-2 gene, which had no association with pathological grading. The value of TOP2A gene used in the prognosis analysis of breast cancer still needed to be investigated.